Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

The pipeline of new drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050.

The number of projects from large pharma companies has shrunk from 92 to 60 medicines in development in the last five years, according to a report from the Access to Medicine Foundation (AMF), a Netherlands-based non-profit group, and the Wellcome Trust.